<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063099</url>
  </required_header>
  <id_info>
    <org_study_id>RD2016-01-01</org_study_id>
    <nct_id>NCT03063099</nct_id>
  </id_info>
  <brief_title>ReNu™ Injection to Treat Hip Osteoarthritis Study</brief_title>
  <official_title>A Pilot Study of ReNu™ Hip Injection: Monitoring the Response of Hip Function and Pain in Patient With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuTech Medical, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Organogenesis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NuTech Medical, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to evaluate changes in hip function and pain in patients with osteoarthritis&#xD;
      receiving the ReNu™ Hip Injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized pilot study evaluating the efficacy of ReNu™ hip&#xD;
      injection on patients with moderate osteoarthritis. The effects will be measured primarily&#xD;
      through patient-reported outcomes questionnaires after a single injection. Patients will be&#xD;
      followed up to 12 months to evaluate improvements using common pain and function subscales.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IHOT12 - International Hip Outcome Tool 12</measure>
    <time_frame>3 &amp; 6 months</time_frame>
    <description>Change from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) Pain Scale</measure>
    <time_frame>3 &amp; 6 months</time_frame>
    <description>Change from Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Harris Hip Score</measure>
    <time_frame>3, 6 &amp; 12 months</time_frame>
    <description>Change from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF12 Score</measure>
    <time_frame>3, 6 &amp; 12 months</time_frame>
    <description>Generic measure of patient's health status change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Assessment Numerical Evaluation (SANE)</measure>
    <time_frame>3, 6 &amp; 12 months</time_frame>
    <description>Measurement tool used to record patient's self-reported change in function from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Osteoarthritis, Hip</condition>
  <arm_group>
    <arm_group_label>ReNu™ Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ReNu™ is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ReNu™ Injection</intervention_name>
    <description>Injection into the hip for the treatment of Osteoarthritis.</description>
    <arm_group_label>ReNu™ Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with moderate hip osteoarthritis determined by a combination of clinical and&#xD;
             radiographic findings&#xD;
&#xD;
          -  Radiographic findings consistent with osteoarthritis as documented by Tonnis&#xD;
             radiographic classification (Grade 1 or 2)&#xD;
&#xD;
          -  Grade 1 Tonnis changes are defined as mild and include increased sclerosis, slight&#xD;
             narrowing of the joint space, no or slight loss of head sphericity&#xD;
&#xD;
          -  Grade 2 Tonnis changes are defined as moderate and include small cysts, moderate&#xD;
             narrowing of the joint space, moderate loss of head sphericity&#xD;
&#xD;
          -  Patients with bilateral grade 1or 2 Tonnis hip osteoarthritis who have bilateral&#xD;
             symptoms may have their more symptomatic hip injected. If equivalent symptoms are&#xD;
             reported by the patient, then the patient will choose which hip is to be injected. The&#xD;
             other Hip can be treated with all standard local interventions that will not have a&#xD;
             prolonged systemic effect that could affect the study hip (for example steroid&#xD;
             injection, cold therapy, soft braces).&#xD;
&#xD;
          -  Between the Ages 18 to 70 with minimum activity level of 2 on the Tegner scale.&#xD;
&#xD;
          -  BMI less than 40&#xD;
&#xD;
          -  Female patients must be actively practicing a contraception method, abstinence, be&#xD;
             surgically sterilized, or be postmenopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pain medication (including NSAIDs) less than 15 days before injection (may take&#xD;
             acetaminophen)&#xD;
&#xD;
          -  Receiving pain medication other than acetaminophen for conditions unrelated to&#xD;
             osteoarthritis of the index hip&#xD;
&#xD;
          -  Regular use of anticoagulants, such as Coumadin, dabigatran or rivaroxaban; use of&#xD;
             antiplatelet medications are not a reason for exclusion&#xD;
&#xD;
          -  History of substance abuse.&#xD;
&#xD;
          -  Failure to agree NOT to take additional hip symptom modifying drugs, other than&#xD;
             acetaminophen, during the course of the study without reporting to the study team&#xD;
&#xD;
          -  Pregnancy or desire to become pregnant during study duration&#xD;
&#xD;
          -  Corticosteroid injection into the index hip within 6 months&#xD;
&#xD;
          -  Viscosupplement injection into the index hip within 6 months&#xD;
&#xD;
          -  Previous open or arthroscopic hip surgery of the involved index hip within the&#xD;
             previous 6 months&#xD;
&#xD;
          -  Open or arthroscopic surgery of the contralateral hip within the last 6 months&#xD;
&#xD;
          -  Worker compensation&#xD;
&#xD;
          -  Acute index hip injury (injury within 3 months)&#xD;
&#xD;
          -  History of Diabetes mellitus&#xD;
&#xD;
          -  History of solid organ or hematologic transplantation&#xD;
&#xD;
          -  History of rheumatoid arthritis or other autoimmune disorder&#xD;
&#xD;
          -  Diagnosis of a non-basal cell malignancy within the preceding 5 years&#xD;
&#xD;
          -  Infection requiring antibiotic treatment within the preceding 3 months&#xD;
&#xD;
          -  Current therapy with any immunosuppressive medication, including corticosteroids at a&#xD;
             dose &gt; 5 mg per day&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katie Mowry, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Organogenesis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Medicine Orthopaedic Surgery</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

